Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06187883
Other study ID # MersinTRHlfcn
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 21, 2023
Est. completion date December 6, 2023

Study information

Verified date April 2024
Source Mersin Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In the current retrospective cohort study, conducted by both pain specialists and neurophysiologists, the primary outcome was to search for the effect of obesity on the efficacy of PRF of LFCN in refractory MP for 6 months. Secondary outcomes were to identify the clinical and diagnostic features of the MP.


Description:

In the current retrospective cohort study, conducted by both pain specialists and neurophysiologists, the primary outcome was to search for the effect of obesity on the efficacy of PRF of LFCN in refractory MP for 6 months. Secondary outcomes were to identify the clinical and diagnostic features of the MP.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 6, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - older than 18 years treated with PRF neuromodulation of LFCN for MP - followed up at least 6 months in the pain clinic of the tertiary hospital between January 2020 and August 2023. Exclusion Criteria: - inadequate follow-up or missing documentation - If a new analgesic drug was prescribed during the follow-up period that could affect the evaluation of outcomes, the patients were also excluded. - Patients who missed appointments, or were unable to communicate with; were not included in the study. - Patients with secondary entrapment neuropathy (e.g., diabetes, inflammatory arthritis, hypothyroidism), malignancy, pregnancy, skin infection in the inguinal region or dermatitis, lumbar radiculopathy, polyneuropathy, and cardiac pacemakers were excluded. - In the SSEP analysis, when the latency of LFCN was not evaluated in both sides, these patients were not also included in the study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Suna Askin Turan Mersin

Sponsors (1)

Lead Sponsor Collaborator
Mersin Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary response to PRF loss of neuropathic pain, lasting at least 6 months was defined as a positive categorical outcome. Neuropathic pain was assessed with Douleur Neuropathique 4 questionnaire (DN4) at baseline, and at 1., 3, 6 months by the pain specialist authors. DN4 consisted of 10 items. The first seven items were associated with the patients' subjective compliants related to pain and sensational variations while the last three items were associated with the clinical findings. Those patients who had a score = 4were considered to have neuropathic pain. Patients with a positive outcome at the 1 or 3 month follow-up,but did not come again were excluded from the study. After the data collection, the patients wer divided into two groups: responders with a positive outcome and nonresponders with a negative outcome.MP for 6 months. Age, sex, body mass index (BMI), employment, tight clothing, belts, carrying things at the back of pants were asked in detail at the initial visit of the Pain Clinic. 6 months
Secondary Secondary outcomes were to identify the clinical and diagnostic features of the MP Secondary outcomes were to identify the clinical and diagnostic features of the MP. The outcome was assesed by the clinical and electrophysiological data collected from the hospital records. The data was analyzed deeply. 6 months
See also
  Status Clinical Trial Phase
Completed NCT04747119 - Effect of MET on Meralgia Paraesthesia Postpartum "Muscle Energy Technique" N/A
Completed NCT02577510 - Comparing Ways to Freeze the Nerve That Provides Thigh Sensation Phase 3
Withdrawn NCT04046406 - Pelvic Pain Treated With MR-guided Cryoanalgesia N/A
Recruiting NCT05893732 - HILT for Meralgia Paresthetica: A Randomized Controlled Trial N/A
Completed NCT06251882 - Efficacy of Ultrasound-guided Injection of 5% Dextrose for Meralgia Paresthesia N/A
Completed NCT04004052 - Conservative Treatment and Ultrasound Guided Injection for Treatment Meralgia Paresthetica N/A
Completed NCT04499911 - Efficacy of Neural Prolotherapy in Treatment of Meralgia Paresthetica N/A